Test Code NGSHM MayoComplete Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing, Varies
Useful For
Evaluation of known or suspected hematologic neoplasms, specifically of myeloid origin (eg, acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelodysplastic/myeloproliferative neoplasm, unexplained cytopenias) at the time of diagnosis or possibly disease relapse
Aiding in determining diagnostic classification
Providing prognostic or therapeutic information for helping guide clinical management
Evaluating patients with suspected VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome
Determining the presence of new clinically important gene mutation changes at relapse
Testing Algorithm
For more information see:
-Acute Leukemias of Ambiguous Lineage Testing Algorithm
-Acute Myeloid Leukemia: Testing Algorithm
-Acute Myeloid Leukemia: Relapsed with Previous Remission Algorithm
-Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation
Special Instructions
- Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation
- Hematopathology Patient Information
- Acute Leukemias of Ambiguous Lineage Testing Algorithm
- Acute Myeloid Leukemia: Testing Algorithm
- Acute Myeloid Leukemia: Relapsed with Previous Remission Algorithm
- Mast Cell Disorder: Diagnostic Algorithm, Bone Marrow
- Targeted Genes Interrogated by Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing
Reporting Name
Myeloid Neoplasms, NGS, VSpecimen Type
VariesShipping Instructions
Peripheral blood and bone marrow specimens must arrive within 14 days of collection.
Necessary Information
The following information is required:
1. Clinical diagnosis
2. Pertinent clinical history, including disease phase (diagnostic, remission, relapse/refractory) and therapy status (especially if patient has received a hematopoietic stem cell transplant).
3. Clinical or morphologic suspicion
4. Date of collection
5. Specimen source
Specimen Required
Submit only 1 of the following specimens:
Preferred Specimen Type: Bone marrow aspirate
Container/Tube:
Preferred: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Green top (sodium heparin)
Specimen Volume: 2 mL
Collection Instructions:
1. Invert several times to mix bone marrow.
2. Send bone marrow specimen in original tube. Do not aliquot.
3. Label specimen as bone marrow.
Specimen Stability: Ambient (preferred)/Refrigerate
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Green top (sodium heparin)
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
3. Label specimen as blood.
Specimen Stability: Ambient (preferred)/Refrigerate
Specimen Type: Extracted DNA from blood or bone marrow
Container/Tube: 1.5- to 2-mL tube with indication of volume and concentration of the DNA
Specimen Volume: Entire specimen
Collection Instructions: Label specimen as extracted DNA and source of specimen
Specimen Stability: Frozen (preferred)/Refrigerate/Ambient
Specimen Minimum Volume
Blood, Bone marrow: 1 mL
Extracted DNA: 100 mcL at 20 ng/mcL concentration
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Varies | 14 days |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | OK |
Bone marrow biopsies Slides Paraffin shavings or frozen tissues Paraffin-embedded tissues Paraffin-embedded bone marrow aspirates Moderately to severely clotted |
Reject |
Reference Values
An interpretive report will be provided.
Day(s) Performed
Monday through Friday
Report Available
16 to 21 daysSpecimen Retention Time
Whole blood, bone marrow: 2 weeks; Extracted DNA: 3 monthsPerforming Laboratory
Mayo Clinic Laboratories in RochesterCPT Code Information
81450
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
NGSHM | Myeloid Neoplasms, NGS, V | In Process |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
MP024 | Specimen Type | 31208-2 |
NGSD | Indication for Test | 42349-1 |
601696 | NGSHM Result | No LOINC Needed |
37276 | Pathogenic Mutations Detected | 82939-0 |
37283 | Interpretation | 69047-9 |
37282 | Clinical Trials | 82786-5 |
37277 | Variants of Unknown Significance | 93367-1 |
37278 | Additional Notes | 48767-8 |
37279 | Method Summary | 85069-3 |
37420 | Disclaimer | 62364-5 |
37280 | OncoHeme Panel Gene list | 36908-2 |
37287 | Reviewed By: | 18771-6 |
Forms
1. Hematopathology Patient Information (T676)
2. If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.
Genetics Test Information
This test includes next-generation sequencing to evaluate for the following 47 genes and select intronic regions: ANKRD26, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KDM6A, KIT, KRAS, MPL, NF1, NPM1, NRAS, PHF6, PPM1D, PTPN11, RAD21, RUNX1, SETBP1, SH2B3, SF3B1, SMC3, SRSF2, STAG2, STAT3, TERT, TET2, TP53, U2AF1, UBA1, WT1, and ZRSR2.
For a list of genes and exons targeted by this test see Targeted Genes Interrogated by Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing.